Adebrelimab
- Generic Name
- Adebrelimab
- Drug Type
- Biotech
- CAS Number
- 2247114-85-6
- Unique Ingredient Identifier
- 1XBY50W1OX
- Background
Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).
- Indication
用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsColorectal CancerNon-Small Cell Lung Cancer
- Interventions
- Drug: Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 762
- Registration Number
- NCT06963502
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
🇨🇳Sun Yat-sen University Cancer Center, Shanghai, China
Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer Non-resectablePancreatic Cancer Metastatic
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Jin Xu
- Target Recruit Count
- 46
- Registration Number
- NCT06916975
- Locations
- 🇨🇳
Fudan University ShangHai Cancer Center, ShangHai, China
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
- Conditions
- Lung Cancer, Small CellLimited-stage Small Cell Lung Cancer (LS-SCLC)
- Interventions
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-25
- Target Recruit Count
- 30
- Registration Number
- NCT06914050
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma(HCC)
- Interventions
- Drug: FOLFOX4Procedure: HAICProcedure: Local treatmentDrug: The original treatment regimen
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Nanjing Tianyinshan Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06893887
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
- Conditions
- Gastric CancerHER2 + Gastric CancerPD-L1 PositiveCLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
- Interventions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 140
- Registration Number
- NCT06881017
Second-line Immunotherapy for ES-SCLC
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Target Recruit Count
- 30
- Registration Number
- NCT06853678
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT06786312
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Fujian Provincial Hospital, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
- Conditions
- HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
- Interventions
- First Posted Date
- 2025-01-16
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT06778031
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
- Target Recruit Count
- 52
- Registration Number
- NCT06776770
- Locations
- 🇨🇳
Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen, Guangdong, China
Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer
- Conditions
- Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Interventions
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Second Affiliated Hospital of Nanchang University
- Target Recruit Count
- 37
- Registration Number
- NCT06773156
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.